PD- 1 blockade activates PD- 1-expressing Treg cells and inhibits effector T cells, including CD8+ T cells, which play a crucial role in killing cancer cells in the host, ultimately leading to treatment failure (Wherry and Kurachi, 2015). This evidence concerns the gene RPL17 and cancer.